227 related articles for article (PubMed ID: 14727938)
1. Spotlight on ramipril in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
[TBL] [Abstract][Full Text] [Related]
2. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
[TBL] [Abstract][Full Text] [Related]
3. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
[TBL] [Abstract][Full Text] [Related]
4. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
5. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
6. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
7. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
8. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
9. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
Anderson VR; Perry CM; Robinson DM
Am J Cardiovasc Drugs; 2006; 6(6):417-32. PubMed ID: 17192135
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
11. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Arnold JM; Yusuf S; Young J; Mathew J; Johnstone D; Avezum A; Lonn E; Pogue J; Bosch J;
Circulation; 2003 Mar; 107(9):1284-90. PubMed ID: 12628949
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term therapy with ramipril in high-risk women.
Lonn E; Roccaforte R; Yi Q; Dagenais G; Sleight P; Bosch J; Suhan P; Micks M; Probstfield J; Bernstein V; Yusuf S;
J Am Coll Cardiol; 2002 Aug; 40(4):693-702. PubMed ID: 12204499
[TBL] [Abstract][Full Text] [Related]
15. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
Marre M; Lievre M; Chatellier G; Mann JF; Passa P; Ménard J;
BMJ; 2004 Feb; 328(7438):495. PubMed ID: 14960504
[TBL] [Abstract][Full Text] [Related]
16. Ramipril in the treatment of vascular diseases.
Rokoss MJ; Teo KK
Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
18. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Mann JF; Gerstein HC; Pogue J; Bosch J; Yusuf S
Ann Intern Med; 2001 Apr; 134(8):629-36. PubMed ID: 11304102
[TBL] [Abstract][Full Text] [Related]
19. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
Kjøller-Hansen L; Steffensen R; Grande P
J Am Coll Cardiol; 2000 Mar; 35(4):881-8. PubMed ID: 10732883
[TBL] [Abstract][Full Text] [Related]
20. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
Dagenais GR; Yusuf S; Bourassa MG; Yi Q; Bosch J; Lonn EM; Kouz S; Grover J;
Circulation; 2001 Jul; 104(5):522-6. PubMed ID: 11479247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
